eli lilly and company zepbound - Search News

Order byBest matchMost fresh

News

Lilly, Zepbound

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine and presented at the European Congress on Obesity.

Continue reading

Stocktwits on MSN · 1d

· 1d · on MSN

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

· 11d · on MSN

Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health

16h

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

12d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

13don MSN

Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Results that may be inaccessible to you are currently showing.

Hide inaccessible results